Rebif’s New Formulation Delayed By FDA
Merck Serono says it is in discussions with FDA to answer outstanding questions over the new formulation of the multiple sclerosis drug.
Merck Serono says it is in discussions with FDA to answer outstanding questions over the new formulation of the multiple sclerosis drug.